Actively Recruiting
Study of Weekly Low-Dose Decitabine and Venetoclax as Maintenance Therapy in Adults with High-Risk Myeloid Malignancies After Stem Cell Transplant
Led by Benjamin Tomlinson · Updated on 2026-10-08
20
Participants Needed
2
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new maintenance therapy aimed at preventing relapse and improving survival in adults with acute myeloid leukemia or myelodysplastic syndromes who have undergone allogeneic stem cell transplant. This study focuses on a gentler chemotherapy approach using low doses of decitabine and venetoclax to control residual cancer cells with fewer side effects. The trial addresses the challenge of post-transplant relapse, which remains common and difficult to manage. Participants will receive weekly low-dose decitabine injections followed about 6 to 8 hours later by an oral dose of venetoclax. This treatment will continue for up to one year, or until relapse or unacceptable side effects occur despite dose adjustments. Alongside the study treatment, participants will continue receiving standard post-transplant care and monitoring according to institutional practices. Throughout the study, participants will meet with their study team at the start, midpoint, and end to undergo bone marrow testing. Researchers will monitor safety by assessing dose limiting toxicities and treatment feasibility over one year. The study will also track relapse-free survival. Participants will be closely followed during treatment with regular visits and laboratory assessments to evaluate the effects and tolerability of the therapy.
CONDITIONS
Brief Title
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Research Team
B
Benjamin Tomlinson, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here